They discovered that mice with GBT and overexpression of the vascular endothelial growth factor C (VEGF-C) demonstrate a better response to anti-tumor therapy, such as the combination of anti-programmed death-1 protein (PD1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blockade. This evidence concerns the gene VEGFC and neoplasm.